Indication
Post Essential Thrombocythemia Myelofibrosis
3 clinical trials
4 products
Product
parsaclisibClinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With MyelofibrosisStatus: Active (not recruiting), Estimated PCD: 2023-08-03
Product
ruxolitinibProduct
placeboClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to RuxolitinibStatus: Active (not recruiting), Estimated PCD: 2023-08-16
Clinical trial
Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]Status: Recruiting, Estimated PCD: 2025-03-01
Product
reparixin